You just read:

Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)

News provided by

Mallinckrodt plc

Aug 15, 2019, 06:45 ET